RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Purpose: The lack of biomarkers that can distinguish aggressive from indolent prostate cancer has caused substantial overtreatment of clinically insignificant disease. Here, by genome-wide DNA methylome profiling, we sought to identify new biomarkers to improve the accuracy of prostate cancer diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Siri H., Switnicki, Michal, Moller, Mia, Haldrup, Christa, Storebjerg, Tine M., Hedegaard, Jakob, Nordentoft, Iver, Hoyer, Soren, Borre, Michael, Pedersen, Jakob S., Wild, Peter J., Park, Jong Y., Orntoft, Torben F., Sorensen, Karina D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351588/
https://www.ncbi.nlm.nih.gov/pubmed/28052017
http://dx.doi.org/10.18632/oncotarget.14391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351588/
https://www.ncbi.nlm.nih.gov/pubmed/28052017
http://dx.doi.org/10.18632/oncotarget.14391

Ejemplares similares